All In Biotech

Drug Trial Radar · NCT06216366

Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers

Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety/Tolerability of IV Rhu-pGSN as a Pre- or Post-Exposure Intervention to Mitigate Proinflammatory Responses to Decompression After High Pressure in a Hyperbaric Chamber

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Aug 15, 2025

Primary completion

Sep 30, 2025

Study completion Nov 30, 2025

Sponsor

Lead sponsor
BioAegis Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jan 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Healthy trained SCUBA divers will be randomized into three groups and exposed to a high-pressure profile in a hyperbaric chamber. The high-pressure profile simulates the pressure at a depth of 30 meters of sea water (MSW) for 35 minutes. In the control group, the subjects will receive intravenous normal saline immediately before and after the high-pressure exposure. The second group will receive intravenous recombinant human gelsolin (rhu-pGSN) 24 mg/kg immediately prior to the exposure, and saline post-exposure. The third group will receive saline pre-exposure and rhu-pGSN post-exposure. Blood samples will be collected at multiple time points pre- and post-exposure to assess levels of inflammatory markers, including interleukin (IL)-1β. Other assessments include screening for gas bubbles, a validated questionnaire to assess the incidence of clinical decompression sickness (DCS), measurement of plasma gelsolin (pGSN) levels, and measurement of anti-pGSN antibodies.

Conditions

  • Decompression Sickness

Interventions

  • Sodium Chloride 0.9% Inj pre-exposureDrug

    Sterile normal saline 0.9% administered IV as a placebo immediately before hyperbaric chamber exposure

  • Sodium Chloride 0.9% Inj post-exposureDrug

    Sterile normal saline 0.9% administered IV as a placebo immediately after hyperbaric chamber exposure

  • Recombinant human plasma gelsolin pre-exposureDrug

    rhu-pGSN administered IV at a dose of 24 mg/kg immediately before hyperbaric chamber exposure

  • Recombinant human plasma gelsolin post-exposureDrug

    rhu-pGSN administered IV at a dose of 24 mg/kg immediately after hyperbaric chamber exposure

  • Hyperbaric chamberOther

    High-pressure profile equivalent 35 minutes at a depth of 30 meters of sea water

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Interleukin (IL)-1βTime frame: At baseline, during and after exposure, and afterward at 60, 120, and 240 minutes, at 24 hours, and at day 14
  2. Adverse EventsTime frame: 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Maryland School of Medicine

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.